)
Janine Sengstack, PhD
Co-founder & CSO
Junevity
Dr. Janine Sengstack is co-founder and CSO of Junevity, a biotechnology company on a mission to extend healthy human lifespan by resetting gene networks. Built on a decade of work originating in Sengstack’s PhD lab at UCSF, Junevity’s RESET platform is the first to combine human disease data, machine learning, and siRNA to unlock novel therapeutic targets. Their lead program, JUN_01, is a liver-targeted siRNA for Type 2 diabetes, designed for the 10+ million patients who remain not at target HbA1c despite GLP-1s and other medications, with just 1-2 doses per year. Junevity is preparing to initiate first-in-human clinical trials for JUN_01 in Q4 2026. Junevity has a growing pipeline in metabolism and neurodegeneration. Sengstack holds a PhD in cell biology from UCSF and a BS summa cum laude from Cal Poly, SLO.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}